Androgens in Health and Disease.pdf - E Library

346 Richmond and Rogol
46. Stanhope R, Buchanan CR, Fenn GC, Preece MA. Double blind placebo controlled trial of low dose
oxandrolone in the treatment of boys with constitutional delay of growth and puberty. Arch Dis Child
1988;63:501–505.
47. Rosenfeld RG, Frane J, Attie KM, et al. Six-year results of a randomized, prospective trial of human
growth hormone and oxandrolone in Turner syndrome. J Pediatr 1992;121:49–55.
48. Nilsson KO, Albertsson-Wikland K, Alm J, et al. Improved final height in girls with Turner’s syndrome
treated with growth hormone and oxandrolone. J Clin Endocrinol Metab 1996;81:635–640.
49. Metzger DL, Kerrigan JR. Androgen receptor blockade with flutamide enhances growth hormone
secretion in late pubertal males: evidence for independent actions of estrogen and androgen. J Clin
Endocrinol Metab 1993;76:1147–1152.
50. Metzger DL, Kerrigan JR. Estrogen receptor blockade with tamoxifen diminishes growth hormone
secretion in boys: evidence for a stimulatory role of endogenous estrogens during male adolescence.
J Clin Endocrinol Metab 1994;79:513–518.
51. Louis O, Demeirleir K, Kalender W, et al. Low vertebral bone density values in young non-elite female
runners. Int J Sports Med 1991;12:214–217.
52. Slemenda CW, Reister TK, Hui SL, et al. Influences on skeletal mineralization in children and adolescents:
evidence for varying effects of sexual maturation and physical activity. J Pediatr
1994;125:201–207.
53. Matkovic V, Jelic T, Wardlaw GM, et al. Timing of peak bone mass in Caucasian females and its
implication for the prevention of osteoporosis. Inference from a cross-sectional model. J Clin Invest
1994;93:799–808.
54. Bass S, Delmas PD, Pearce G, Hendrich E, et al. The differing tempo of growth in bone size, mass,
and density in girls is region-specific. J Clin Invest 1999;104:795–804.
55. Finkelstein JS, Klibanski A, Neer RM, et al. Osteoporosis in men with idiopathic hypogonadotropic
hypogonadism. Ann Intern Med 1987;106:354–361.
56. Finkelstein JS, Neer RM, Biller BM, et al. Osteopenia in men with a history of delayed puberty. N Engl
J Med 1992;326:600–604.
57. Abu EO, Horner A, Kusec V, et al. The localization of androgen receptors in human bone. J Clin
Endocrinol Metab 1997;82:3493–3497.
58. Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings
caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab
1995;80(12):3689–3698.
59. Bilezikian JP, Morishima A, Bell J, Grumbach MM. Increased bone mass as a result of estrogen
therapy in a man with aromatase deficiency. N Engl J Med 1998;339:599–603.
60. Houchin LD, Rogol AD. Androgen replacement in children with constitutional delay of puberty: the
case for aggressive therapy. Baillieres Clin Endocrinol Metab 1998;12:427–440.
61. Sanayama K, Noda H, Konda S, et al. Spontaneous growth hormone secretion and plasma somatomedin-C
in children of short stature. Endocrinol Jpn 1987;34:627–633.
62. Kerrigan JR, Martha PM Jr, Blizzard RM, Christie CM, Rogol AD. Variations of pulsatile growth
hormone release in healthy short prepubertal boys. Pediatr Res 1990;28:11–14.
63. Crowne EC, Shalet SM, Wallace WH, et al. Final height in boys with untreated constitutional delay
in growth and puberty. Arch Dis Child 1990;65:1109–1112.
64. Bertelloni S, Baroncelli GI, Battini R, et al. Short-term effect of testosterone treatment on reduced
bone density in boys with constitutional delay of puberty. J Bone Miner Res 1995;10:1488–1495.
65. Bourguignon JP. Linear growth as a function of age at onset of puberty and sex steroid dosage:
therapeutic implications. Endocr Rev 1988;9:467–488.